VICO

Vicore Pharma Holding

Market Cap 298.3M
Today
Day High
19.35
18.7
Day Low
17.65
Day Open
18.00
Prev Close
17.30
VWAP
18.6
Volume
76K
Turnover
1.418M
Top Broker
AVA
VWAP
16.4
Avg Volume
13K
Avg Turnover
0.209M
Top Brokers
AVA/ENS
VWAP
16.1
Avg Volume
16K
Avg Turnover
0.255M
Top Brokers
AVA/ENS
VWAP
16.2
Avg Volume
12K
Avg Turnover
0.189M
Top Brokers
AVA/NON
52 week summary
Price Range
14.9
Last
40.0
Beta
N/A
Market Cap
298.3M
Total Return
-5.5%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
15.9M
Next Earnings Date
8 May
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -9.3%
Change 12 Months -7.5%
Volume Trend
Average Volume 10 vs 60 Days 48.7%
Price VS
52 Week High -53.3%
50 Day Moving Average 11.4%
200 Day moving Average -11.8%

Add article markers

Compare Vicore Pharma Holding to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Per Jansson, CEO
  • Executive board
  • Leif Darner, Chairman of the board
Source: Millistream
Major Owners Equity Votes
Protem Wessman inkl familj 14.8%
14.8%
Swedbank Robur 9.9%
9.9%
HBM Healthcare Investments (Cayman) 7.6%
7.6%
Kjell Stenberg 7.2%
7.2%
Pomona-gruppen 5.1%
5.1%
Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.